Trials / Completed
CompletedNCT01474278
A Study of RO5028442 in Adult Male High-Functioning Autistic Patients
A Multi-centre, Randomized, Double-blind, Placebo-controlled, Two-period Cross-over, Exploratory Biomarker and Safety and Tolerability Study of a Single Dose of RO5028442 in Adult Male High-functioning Autistic Patients
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
This multi-center, randomized, double-blind study will evaluate exploratory biomarkers and the safety and tolerability of a single dose of RO5028442 in adult male high-functioning autistic patients. In a cross-over design, patients will be randomized to receive either a single dose of RO5028442 or matching placebo with a washout period of 7-14 days. Anticipated time on study is up to approximately 9 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Single dose |
| DRUG | RO5028442 | Single dose |
Timeline
- Start date
- 2011-12-01
- Primary completion
- 2013-03-01
- Completion
- 2013-03-01
- First posted
- 2011-11-18
- Last updated
- 2016-11-02
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01474278. Inclusion in this directory is not an endorsement.